Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Chief Scientific Officer | March 01, 2022 | March 03, 2022 |
| Biohaven Ltd.BHVN · Entity 4379 | Chief Scientific Officer | February 27, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date March 01, 2022 · Filed March 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 11,500 |
Reported balance
After 2022-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 11,500 · Balance 11,500 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.20 · Expires 2032-03-01 | Direct | 41,000 |
Reported balance
After 2022-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-01 · Grant · Acquired 41,000 · Balance 41,000 F3: This option was granted on March 1, 2022. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.
F3: This option was granted on March 1, 2022. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Biohaven Ltd.
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.52 · Expires 2036-02-27 | Direct | 175,000 |
Reported balance
After 2026-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-27 · Grant · Acquired 175,000 · Balance 175,000 F1: The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2026 Filed Mar 3, 2026 23:07 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 175,000 | $0.00 Strike: $11.52 | $0.00 |
DisclosureSEC source: 0001798876-26-000004 · wk-form4_1772579259.xml · derivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Shares · 175,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| January 05, 2026 Filed Jan 8, 2026 02:32 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionRestricted Share Unit Award · Derivative | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001798876-26-000002 · wk-form4_1767839521.xml · derivative · entry 4 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Shares · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F3 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted 19,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document |
| January 05, 2026 Filed Jan 8, 2026 02:32 UTC | Biohaven Ltd. BHVN · Entity 4379 | Tax withholdingCommon Shares | 2,381 | $9.93 | $23,643.33 |
DisclosureSEC source: 0001798876-26-000002 · wk-form4_1767839521.xml · nonDerivative · entry 2 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,715 F2 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. F1 · balance_after: This balance includes 544 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2025. Read SEC document |
| January 05, 2026 Filed Jan 8, 2026 02:32 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001798876-26-000002 · wk-form4_1767839521.xml · nonDerivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance includes 544 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2025. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:51 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionRestricted Share Unit Award · Derivative | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000006 · wk-form4_1736301080.xml · derivative · entry 6 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Shares · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F3 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted 19,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:51 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantRestricted Share Unit Award · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000006 · wk-form4_1736301080.xml · derivative · entry 5 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Shares · 19,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F3 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted 19,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:51 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 112,000 | $0.00 Strike: $38.64 | $0.00 |
DisclosureSEC source: 0001935979-25-000006 · wk-form4_1736301080.xml · derivative · entry 4 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Shares · 112,000 shares Expires 2035-01-05 F2 · derivative.exercise_date: The shares underlying this option vest in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:51 UTC | Biohaven Ltd. BHVN · Entity 4379 | Tax withholdingCommon Shares | 2,331 | $38.64 | $90,069.84 |
DisclosureSEC source: 0001935979-25-000006 · wk-form4_1736301080.xml · nonDerivative · entry 2 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,802 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:51 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000006 · wk-form4_1736301080.xml · nonDerivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 11:30 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 30,000 | $33.58 | $1,007,490.00 |
DisclosureSEC source: 0001562180-24-005174 · primarydocument.xml · nonDerivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA Disclosed balance after: 30,000 Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 01:08 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 96,250 | $0.00 Strike: $41.93 | $0.00 |
DisclosureSEC source: 0001562180-24-000286 · primarydocument.xml · derivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,250 Underlying: Common Shares · 96,250 shares Expires 2034-01-02 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on January 2, 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| November 02, 2023 Filed Nov 7, 2023 01:32 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 78,750 | $0.00 Strike: $29.49 | $0.00 |
DisclosureSEC source: 0001562180-23-007576 · primarydocument.xml · derivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Shares · 78,750 shares Expires 2033-11-02 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on November 2, 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:40 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007083 · primarydocument.xml · derivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Shares · 300,000 shares Expires 2032-10-04 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 41,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001439222-22-000030 · wf-form4_164634187837787.xml · derivative · entry 2 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Underlying: Common stock · 41,000 shares Expires 2032-03-01 F3 · derivative.exercise_date: This option was granted on March 1, 2022. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 11,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000030 · wf-form4_164634187837787.xml · derivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common stock · 11,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 2,041 | $29.08 | $59,352.28 |
DisclosureSEC source: 0001439222-22-000019 · wf-form4_164565065647827.xml · nonDerivative · entry 2 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,752 Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 6,874 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000019 · wf-form4_164565065647827.xml · derivative · entry 3 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,874 Underlying: Common stock · 6,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 6,874 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000019 · wf-form4_164565065647827.xml · nonDerivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 3,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000005 · wf-form4_164487282368778.xml · derivative · entry 3 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,333 Underlying: Common stock · 3,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,073 | $31.43 | $33,719.03 |
DisclosureSEC source: 0001439222-22-000005 · wf-form4_164487282368778.xml · nonDerivative · entry 2 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,919 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000005 · wf-form4_164487282368778.xml · nonDerivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 3,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000001 · wf-form4_164184875990924.xml · derivative · entry 3 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,437 Underlying: Common stock · 3,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on January 6, 2020. Beginning on January 6, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on January 6, 2020. Beginning on January 6, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,205 | $32.58 | $39,259.02 |
DisclosureSEC source: 0001439222-22-000001 · wf-form4_164184875990924.xml · nonDerivative · entry 2 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,325 Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000001 · wf-form4_164184875990924.xml · nonDerivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:23 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 44,000 | $0.00 Strike: $56.68 | $0.00 |
DisclosureSEC source: 0001439222-21-000006 · wf-form4_161316498183368.xml · derivative · entry 2 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common stock · 44,000 shares Expires 2031-02-10 F3 · derivative.exercise_date: This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:23 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000006 · wf-form4_161316498183368.xml · derivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common stock · 11,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| January 06, 2021 Filed Apr 15, 2021 20:46 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 3,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000033 · wf-form4_161851957884956.xml · derivative · entry 3 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,874 Underlying: Common stock · 3,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on January 6, 2020. Beginning on January 6, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on January 6, 2020. Beginning on January 6, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| January 06, 2021 Filed Apr 15, 2021 20:46 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,191 | $44.09 | $52,506.31 |
DisclosureSEC source: 0001439222-21-000033 · wf-form4_161851957884956.xml · nonDerivative · entry 2 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,093 Read SEC document |
| January 06, 2021 Filed Apr 15, 2021 20:46 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000033 · wf-form4_161851957884956.xml · nonDerivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 2,027 | $40.64 | $82,377.28 |
DisclosureSEC source: 0001439222-20-000029 · wf-form4_158698234017383.xml · nonDerivative · entry 2 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,847 Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 6,874 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000029 · wf-form4_158698234017383.xml · derivative · entry 3 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,748 Underlying: Common stock · 6,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified commercial milestone was determined to have been met on April 13, 2020, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified commercial milestone was determined to have been met on April 13, 2020, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 6,874 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000029 · wf-form4_158698234017383.xml · nonDerivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 10,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000003 · wf-form4_157851867389419.xml · derivative · entry 2 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,311 Underlying: Common stock · 10,311 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 6, 2020. Beginning on January 6, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on January 6, 2020. Beginning on January 6, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 47,007 | $0.00 Strike: $48.49 | $0.00 |
DisclosureSEC source: 0001439222-20-000003 · wf-form4_157851867389419.xml · derivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,007 Underlying: Common stock · 47,007 shares Expires 2030-01-06 F1 · derivative.exercise_date: This option was granted on January 6, 2020. The shares underlying this option vest as to 25% of the underlying shares on January 6, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.